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Abstract
Purpose To study the therapeutic effects of probiotic
Escherichia coli Nissle 1917 (EcN) in irritable bowel
syndrome (IBS) and identify subgroups benefiting most.
Background Some trials investigating therapeutic effects in
irritable bowel syndrome have shown benefits in IBS
subgroups only. Probiotic treatment seems to be promising.
Methods Patients with irritable bowel syndrome (120;
Rome II) were recruited to a prospective double-blind
study and randomized to either EcN (n=60) or placebo (n=
60) given for 12 weeks. Objectives were to describe
efficacy and safety of EcN in different groups of irritable
bowel syndrome. Outcome was assessed by ‘Integrative
Medicine Patient Satisfaction Scale’.
Results Altogether, the responder rate was higher in the
EcN than in the placebo group. However, only after 10 and
11 weeks, the differences were significant (Δ 20.0% points
[95% CI 2.6; 37.4], p=0.01 and Δ 18.3% points [95% CI
1.0; 35.7], p=0.02, respectively). The best response was
observed in the subgroup of patients with gastroenteritis or
antibiotics prior to irritable bowel syndrome onset (Δ
45.7% points, p=0.029). No significant differences were
observed in any other subgroup. Both treatment groups
showed similar adverse events and tolerance.
Conclusions Probiotic EcN shows effects in irritable bowel
syndrome, especially in patients with altered enteric
microflora, e.g. after gastroenterocolitis or administration
of antibiotics.
Keywords Irritable bowel syndrome.Treatment.
Probiotics.E. coli Nissle 1917.Enteric infections
Introduction
Symptoms of irritable bowel syndrome (IBS) are frequent
among the general population, and they often give reason to
seek for health care. However, individual treatment may be
cumbersome and needs to be improved. Because of
negative results of some trials, recent efforts focused upon
therapeutic studies in selected groups of patients, such as
patients with diarrhea or constipation predominant IBS or
female patients [1].
The etiology of IBS is still not understood. Pathophys-
iological factors which are thought to play a role comprise
alterations of the intestinal milieu, immune activation,
enteric neuromuscular dysfunction and brain–gut axis
dysregulation. All of these factors are influenced by enteric
microbiota [2]. A recent metaanalysis suggests favorable
therapeutic effects of probiotics in IBS [3].
Probiotic microorganisms have been defined as live
microbes that, when administered in adequate amounts,
confer a health benefit on the host [4, 5]. A particularly
well-investigated probiotic strain is Escherichia coli Nissle
1917 (serotype O6:K5:H1) (EcN). For example, its
genomic sequence, the unique lipopolysaccharide and
several of its microbiological properties are defined [6–8].
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MUTAFLOR®. Moreover, in controlled studies, EcN has
demonstrated therapeutic efficacy in functional constipation
[9], diarrhea [10, 11] and also in maintaining remission of
ulcerative colitis [12]. Therefore, here, a study is presented,
which investigated the therapeutic effects of EcN in patients
with IBS. The specific purpose of the study was to identify
subgroups of IBS patients benefiting from probiotic
treatment with EcN.
Patients and methods
Definitions
IBS was defined according to the Rome II criteria [13]:
within the last 12 months, at least 12 weeks (not necessarily
consecutive) of abdominal pain or discomfort and at least
two of the following criteria: (1) relief after defecation and/
or (2) onset associated with a change in frequency of stools
and/or (3) onset associated with a change in form
(appearance) of stools.
In addition, organic disease was excluded by using the
Kruis score [14].
Participants
Patients were included in the study if they fulfilled the
Rome II criteria [13] and if they had a sum of at least 26
points in the Kruis score. At the time of recruitment,
patients between 18 and 65 years had to suffer from at least
three of the following symptoms: diarrhea, constipation,
urgency, abdominal pain, meteorism, flatulence, abdominal
distension, feeling of fullness, borborygmi and/or nausea.
Postinfectious IBS was defined as bacterial intestinal
infection before the occurrence of IBS symptoms.
Specific exclusion criteria were organic intestinal dis-
ease, significant intestinal surgery, functional diarrhea or
constipation not addressed by the definition of IBS and
regular use of laxatives or antidiarrheals, antibiotics,
chronic steroids or immunosuppressants.
Subjects seeking relief of their intestinal complaints were
invited to participate by advertisements in local news-
papers. After general and individual information by the
attending physician (S. Chrubasik), suitable patients gave
their written informed consent and were randomized.
Study design
The trial was designed as a randomized, double-blind,
parallel-group, monocenter study. The study was conducted
in accordance with the declaration of Helsinki (revised
version of South Africa, 1996) and the Note for Guidance
on Good Clinical Practice CPMP/ICH/135/95, 1996.
Sponsorship was given by an unrestricted grant from
Ardeypharm GmbH, Herdecke, Germany. The protocol
was approved by the ethics committee of the Deutsche
Ärztekammer Nordrhein and registered with the Federal
Institute for Drugs and Medical Devices (the German
regulatory authority). The study was registered in the
German Clinical Trials Register (registration number
DRKS00000416).
Patients were centrally randomized and allocated 1:1 to
receive either one capsule MUTAFLOR® (with 2.5–25×
10
9 CFU Escherichia coli Nissle 1917) o.d. for 4 days and
thereafter two capsules MUTAFLOR® o.d. throughout the
trial (n=60 patients) or placebo in an identical shape and
order of application (n=60 patients). The study medication
was given for 12 weeks.
Following the inclusion and exclusion criteria, a total of
120 subjects were enrolled, and all received at least one
dose of study medication. Thus, the intention-to-treat
population (ITT) comprised 120 patients for the efficacy
and safety evaluation (Fig. 1).
Objectives/outcome
The primary objective of the study was to describe the
treatment effects of EcN in different groups of IBS and to
compare the contentment of the patients with the treatment
between the two groups receiving either EcN or placebo.
In addition, secondary efficacy variables included qual-
ity of life and changes in symptoms such as stool frequency
and consistency, urgency, pain frequency and intensity,
flatulence, distension and nausea. Also, drug safety and
tolerance were monitored throughout the study.
Clinical evaluation
Clinic visits were appointed for weeks 0, 4, 8 and 12 or at
termination of the study. Therapeutic success and safety
were assessed according to diaries filled in by patients
through the study. The primary endpoint was defined by
global rating using the ‘Integrative Medicine Patient
Satisfaction Scale’ (IMPSS) [15]. IMPSS offers five
answers of the patient's contentment with therapy: very
much satisfied, little satisfied, undecided, little dissatisfied
and very much dissatisfied. The first two categories (very
much satisfied and little satisfied) were regarded as
successful treatment (‘responder’).
Quality of life was determined by using a health-related
quality of life (HRQL) scoring system for patients with IBS
[16]. This questionnaire comprises a range of 26 items with
response options on a seven-point rating scale. The items
contribute to four domains as follows: bowel symptoms,
fatigue, activity limitations and emotional function.
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according to Good Clinical Practice for clinical trials of
medication in the European Community (91/507/EWG,
CPMP/ICH/135/95). Tolerance of the study medication was
assessed by a four-point scale (very good, good, fair and
poor), and the patient's compliance was checked by pill
counting and the patient's diary. Laboratory analyses,
including CRP, hemoglobin, blood cell count, hematocrit,
ALT, AST, creatinine, bilirubin and alkaline phosphatase,
were performed at the beginning and end of the study.
Study medication
The investigational drug was an enteric-coated capsule,
containing 2.5–25×10
9 viable cells of Escherichia coli
strain Nissle 1917 (MUTAFLOR®, manufactured by
Ardeypharm GmbH, Herdecke, Germany). The placebo
was a capsule not distinguishable from the verum but
without the active substance EcN. Concomitant medica-
tion with possible effects on gastrointestinal function
(according to a given list) was not allowed. The compliance
with the study medication was assessed according to pill
counting.
Statistics
This trial was designed as an explorative study in order to
test for therapeutic efficacy (in all patients and subgroups),
safety and tolerance of EcN in patients with IBS. Because
of the explorative approach of the study (with the objective
of generating hypotheses), a sample size calculation was
not performed.
In accordance with the design of the study, comparison
of the treatment regimens was carried out by means of
descriptive statistical methods. For the purpose of efficacy
analysis, two data sets were defined, the intention-to-treat
(ITT) sample and the per-protocol (PP) sample. The ITT
population includes all patients enrolled (n=120) because
all participants received at least one dose of the study
medication. After exclusion of 21 patients, the PP analysis
set consisted of 99 patients. The most frequent exclusion
criteria were major protocol deviations (17 patients) and
premature study termination (4 patients) (Fig. 1). Addition-
ally, subgroup analyses were planned. Chi-square test (one-
sided, α=0.05) was used for explorative investigation of all
efficacy parameters on whether or not a difference existed
between the two treatment groups. In general, data are
given as mean±SD and have 95% confidence intervals
([95% CI]).
The randomization schedule was generated by means of
SAS®, version 8.2, based on a seed depending random
number generator. The method of randomly permuted
blocks was used (block size 4). Statistical evaluation was
performed by an independent institution (ClinResearch
GmbH, Cologne, Germany) using the program package
SAS®, version 8.2.
120 patients enrolled and randomly assigned 
to treatment
ITT analysis/
Safety analysis
N=120
PP analysis
N=99
60 patients allocated to EcN
2 adverse 
events (AE)
N=2
4 other reasons
5 protocol deviations
N=49
4 protocol 
deviations
5 protocol 
deviations
60 patients allocated to placebo
N=2
2 lack of 
efficacy
3 protocol 
deviations
N=46
54 patients completed study 49 patients completed study
Fig. 1 Flowchart of patient
disposition by treatment group
(all randomized patients,
n=120)
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ThebaselinecharacteristicsoftheITTpopulation(n=120)are
listed in Table 1. The majority of the patients were female
(76.6%). In general, patient demographics were well compa-
rable between the two treatment groups. Of the 60 patients, 6
patients (10%) under EcN and 11 patients (18%) under
placebo left the study before week 12. The following reasons
were stated (multiple reasons possible): inclusion criteria not
met (n=9), non-tolerable adverse events (n=3), lack of
efficacy (n=2), newly appeared exclusion criteria (n=2) and
personal reasons (n=2).
Primary objectives
ClinicalresponsecurvesfortheITTpopulationaredepictedin
Fig. 2. The greatest difference between response rates in
comparison to placebo occurred after 10 weeks, with a
difference of 20.0% ([2.6; 37.4], p=0.01), and after 11 weeks
of treatment, with an 18.3% difference ([1.0; 35.7], p=0.02).
At the end of the study, the difference between the groups
(EcN 53.3%, placebo 41.7%) was 11.6% ([−6.1; 29.4]) and
did not reach statistical significance (p=0.10).
After 12 weeks, 27 of the 51 patients (52.9%) achieved
clinical response in the EcN group, and 23 of the 48
patients (47.9%) achieved clinical response in the placebo
group (PP analysis, p=0.30).
Subgroup analyses
Altogether, females showed higher response rates than males
(females 51.1% vs. males 35.7% at week 12), but differences
between the effects of EcN and placebo were similar in
females (10.8%) and males (10.4%) after 12 weeks.
Additional subgroups, classified to the predominant
symptom at the time of inclusion or according to the
patient's case history, were analyzed (Table 2). The best
therapeutic gain of EcN was observed in patients with prior
bacterial intestinal infection (n=5)(p=0.01) as compared to
placebo. Another 15 patients were given antibiotics prior to
the onset of IBS symptoms. Summing up these patients
with an altered enteric microflora (prior antibiotics and/or
gastroenteritis; multiple entries possible) (n=17), the
difference in the treatment response between EcN and
placebo was 45.7% (p=0.029; Fig. 3).
Therapeutic effects on symptoms recorded throughout
the study
Changes of individual symptoms are depicted in Table 3.I n
both treatment arms, many symptoms improved during the
study. Of particular interest are the highly significant effects
on all qualities of pain such as intensity, duration and
frequency. To note, meteorism and nausea showed signif-
icant improvements only with EcN.
Quality of life
Health-related quality of life (HRQL) improved in both
treatment arms. The baseline score of the EcN group was
111.6±22.2 and improved by 22.8±28.7 points (20.4%).
The respective numbers of the placebo group were 113.8±
22.3 (baseline score) and 20.0±29.3 (improvement)
(17.6%).
Table 1 Demographic and other baseline characteristics of the patients included in the study (intention to treat analysis)
EcN group mean±SD or number
of patients (%)
Placebo group mean±SD or number
of patients (%)
Number of patients 60 60
Females 48 (80%) 44 (73.3%)
Males 12 (20%) 16 (26.7%)
Age [years] 46.3±12.1 45.1±12.7
Duration of symptoms [years] 12.3±11.5 11.7±12.0
Diagnosis of irritable bowel syndrome known since [years] 1.1±3.0 1.3±3.2
Gastroenteritis and/or antibiotics prior to onset of symptoms 10 (16.7%) 7 (11.6%)
Constipation predominant
a 19 (31.7%) 16 (26.7%)
Diarrhea predominant
a 27 (45.0%) 27 (45.0%)
Alternating stool habits
a 34 (56.7%) 37 (61.7%)
Abdominal pain
a 31 (51.7%) 34 (56.7%)
Meteorism
a 50 (83.3%) 56 (93.3%)
Flatulence
a 51 (85.0%) 52 (86.7%)
EcN Escherichia coli Nissle 1917
aPresent at inclusion into the study
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As rated by the patients, overall tolerance was ‘very good’
or ‘good’ in 91.7% of the patients in the EcN group as
compared to 83.3% in the placebo group.
No deaths occurred during this study. Only one adverse
event (AE), a tooth abscess in a patient of the placebo
group, was classified as ‘serious’ due to the necessity for
hospitalization.
A total of 57/120 patients (47.5%) experienced at least
one AE, with 30/60 patients (50%) in the EcN group and
27/60 patients (45.0%) in the placebo group. The most
frequent AE was influenza-like illness (6.7% in both
treatment groups). In general, both treatment groups were
similar with respect to the type and frequency of AEs. No
unexpected alterations were detected in the laboratory
values.
Discussion
Our study is not able to demonstrate a significant effect of
probiotic therapy with EcN on symptoms of IBS in general.
Efficacy of EcN was superior to that of placebo (at best 20%
point difference), but effects are limited and have reached the
level of significance only after weeks 10 and 11 of the 12-
weekstudy period(Fig. 2). The lack of significance may be a
sample size problem. Indeed, recent placebo-controlled IBS
clinical trials demonstrate a similar therapeutic gain of
approximately 10–20% in positive studies [17]. Many
symptoms showed improvement in our study. Those effects
occurred in the EcN group as well as under placebo. This,
again, points to the efficacy of placebo, making it difficult to
demonstrate superior effects of a specific therapy.
Study results of probiotic treatment of IBS show wide
variability. Though pooled data of a metaanalysis [3] were
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Fig. 2 Rate of overall respond-
ers during the 12-week treat-
ment period (n=120, intention
to treat analysis)
Table 2 Responders in subgroups after 12-week treatment (intention to treat analysis, chi- square test, last observation carried forward (LOCF))
Definition of subgroups Rate of responder
EcN group [%] Placebo group [%] p-value (one sided)
Gastroenteritis and/or antibiotics prior to onset of symptoms 60.0 14.3 0.0297
Constipation predominant
a 57.9 50.0 0.3202
Diarrhea predominant
a 51.9 51.9 0.5000
Alternating stool habits
a 61.8 48.6 0.1336
Abdominal pain
a 54.8 50.0 0.3482
Meteorism
a 58.0 48.2 0.1568
Flatulence
a 54.9 44.2 0.1394
Urgency
a 55.6 50.0 0.3208
Nausea
a 63.2 50.0 0.2249
EcN Escherichia coli Nissle 1917
aPresent at inclusion into the study
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contradictory results. A thorough systematic review [18]
concluded that only the probiotic Bifidobacterium infantis
35624 shows efficacy. Apparently, not all probiotics are the
same, and not all probiotics are likely to be effective.
Moreover, it could also be the case that specific probiotics
are only active in specific types of IBS.
Looking into more details of the present study, many
individual symptoms showed impressive amelioration
throughout the study period. However, effects occurred
not only in the EcN group but also, somewhat less, under
placebo. This points to the efficacy of any IBS treatment
known from the international literature, also with placebo,
making it difficult to demonstrate superior effects of a
specific therapy.
Most likely, IBS is not a single entity but rather a
collection of as yet not better definable diseases [19]. Thus,
it seems plausible that not a single effective treatment exists
for all patients. Different effects of a given treatment in
different patient populations are well known [1]. Therefore,
it has been recommended to customize therapies to specific
types of gastrointestinal dysfunction [20]. As one such
specific entity, postinflammatory bowel dysfunction has
recently come into the focus of scientific discussion.
A particular focus of the study was to analyze the
therapeutic effects in subgroups of IBS. The group of
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Fig. 3 Therapeutic success in
patients with antibiotic pretreat-
ment and/or postinfection
(n=17, intention to treat
analysis, chi- square test,
one-sided)
Table 3 Secondary parameters prior to study and after 12-week treatment (intention to treat analysis)
Parameter EcN group mean or number of patients (%) Placebo group mean or number of patients (%)
Prior to study
a Week 12 (LOCF) p-value Prior to study
a Week 12 (LOCF) p-value
Number of stools per week 15.4 11.9 0.0545 12.6 10.3 0.0198
Consistency of stool as deviation from value
4=smooth (1=hard, 7=watery)
1.6 1.2 0.0023 1.6 1.2 0.0184
Flatulence (0=none, 1=little, 2=moderate,
3=severe)
2.0 1.4 <0.0001 2.0 1.5 <0.0001
Meteorism (yes
b) 85.0% 66.7% 0.0164 83.3% 80.0 0.5637
Urgency (yes
b) 46.7% 51.7% 0.5316 58.3% 56.7% 0.8185
Nausea (yes
b) 43.3% 23.3% 0.0073 30.0% 28.3% 0.7630
Pain ‘intensity’
c 61.2 80.2 <0.0001 62.5 79.3 <0.0001
Pain ‘duration’
c 62.9 81.0 <0.0001 63.4 78.7 0.0002
Pain ‘frequency’
c 59.8 81.2 <0.0001 61.4 78.9 0.0001
EcN Escherichia coli Nissle 1917, LOCF last observation carried forward
aData from week before starting treatment
bYes=at least one answer ‘yes’ per week
cPain scale from 0=‘very strong’ to 100=‘no pain’
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the onset of their symptoms showed convincing efficacy.
Such subgroup effects were also reported for another
probiotic [21].
Development of IBS after infectious intestinal diseases has
been reported for several years [22]. A recent metaanalysis
describes a pooled risk estimate revealing a sevenfold
increase in the odds of developing IBS following infectious
gastroenteritis [23]. While postinfectious IBS has been
reported to occur in about 10–30% of patients with
gastroenteritis, the frequency of these particular patients
among all IBS patients is not clear. Changes in neuromotor
function occur even with mild and superficial inflammation
restricted to the mucosa [24]. Mechanisms of postinflamma-
tory functional diseases have been identified, including
continued low-grade inflammation, increased availability of
serotonin, altered nerve structure and expression of novel
receptors [25]. The common link between all of these effects
is thought to be alteration of the enteric microflora. Factors
such as antibiotics, psychological and physical stress, and
certain dietary components have been found to contribute to
intestinal dysbiosis in IBS [26]. In a prospective case–control
study, subjects who were given a course of antibiotics were
more than three times as likely to report more bowel
symptoms 4 months later than controls [27].
Therapeutic effects ofprobiotics can beexplained bymany
mechanisms: either by direct action upon the enteric micro-
flora (cross talk, quorum sensing) or by indirect immuno-
modulatory, antiinflammatory and barrier activities (cross
talk). Recently, persistentchanges in proinflammatory (IL-12)
and antiinflammatory (IL-10) cytokines were demonstrated in
IBS [28]. The administration of probiotic bacteria led not
only to symptomatic improvement but also to normalization
of the IL-12/IL-10 ratio. Cell extracts and even cell debris of
EcN are able to stimulate IL-10 production of peripheral
mononuclear cells [29]. Furthermore, among other effects
EcN has shown to affect intestinal motility [30], it has strong
immunomodulatory properties, it prevents the invasion of
pathogens into the mucosa [31], and it induces the synthesis
of antimicrobial peptides (e.g. human β-defensins, cathelici-
dines) as well as the synthesis of tight-junction proteins in
intestinal epithelial cells [32, 33].
In conclusion, EcN could not achieve significant efficacy
in unselected patients with IBS. But, this exploratory study
aimed to define subgroups of patients with IBS who may
benefit from treatment with the probiotic EcN. Indeed, the
results are promising for the subgroup of IBS patients with
altered enteric flora due to gastroenterocolitis or adminis-
tration of antibiotics. In order to confirm these early results,
appropriate clinical trials are indispensable.
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